A5001591653- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Hepatocellular Carcinoma Treatment and Prognosis
- Brain Metastases and Treatment
- Radiopharmaceutical Chemistry and Applications
- Genetic factors in colorectal cancer
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Renal cell carcinoma treatment
- CAR-T cell therapy research
- Heat shock proteins research
- Chemotherapy-induced cardiotoxicity and mitigation
- HER2/EGFR in Cancer Research
- Lymphoma Diagnosis and Treatment
Institute of Oncology Prof. Dr. Ion Chiricuta
2016-2025
Iuliu Hațieganu University of Medicine and Pharmacy
2015-2025
Hunan Cancer Hospital
2024
Johns Hopkins University
2024
Dana-Farber Cancer Institute
2024
Shanghai Chest Hospital
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
National Cancer Center
2024
Central South University
2024
Sidney Kimmel Cancer Center
2022
We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–small-cell lung cancer after failure of first-line or second-line chemotherapy.
Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as potential biomarker benefit. In this part an open-label, multipart, 3 we examined progression-free survival with nivolumab versus chemotherapy among patients high (≥10 mutations per megabase).
Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however, data from phase 3 trials are needed to confirm these findings.
Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, irinotecan (FOLFIRI) compared with FOLFIRI alone after failure initial treatment for mCRC by tumor KRAS status. Patients Methods mCRC, one prior chemotherapy regimen Eastern Cooperative...
The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib with placebo 1,692 patients refractory advanced non-small-cell lung cancer. We analyzed ISEL tumor biopsy samples to examine relationships between biomarkers and clinical outcome after treatment a placebo-controlled setting.Biomarkers included epidermal growth factor receptor (EGFR) gene copy number by fluorescence situ hybridization (n = 370); EGFR 379) phosphorylated Akt (p-Akt) protein expression 382)...
Purpose For patients with small-cell lung cancer (SCLC), further chemotherapy is routinely considered at relapse after first-line therapy. However, proof of clinical benefit has not been documented. Patients and Methods This study randomly assigned relapsed SCLC as candidates for standard intravenous therapy to best supportive care (BSC) alone (n = 70) or oral topotecan (2.3 mg/m 2 /d, days 1 through 5, every 21 days) plus BSC (topotecan; n 71). Results In the intent-to-treat population,...
Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti-epithelial cell-adhesion molecule x anti-CD3) represents targeted immunotherapy for the intraperitoneal (i.p.) malignant secondary to epithelial cancers. In this phase II/III trial (EudraCT 2004-000723-15; NCT00836654), cancer patients (n = 258) with recurrent symptomatic resistant conventional chemotherapy were randomized paracentesis plus...
In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (previously published). Here, we report EGFR mutation analyses of plasma-derived, circulating-free tumor DNA.
Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).gefitinib 250 mg day(-1) until progression. Primary endpoint: objective response rate (ORR). Secondary endpoints: disease control (DCR), progression-free survival (PFS), overall (OS) safety/tolerability. Pre-planned exploratory objective:...
Targeting the programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) shown evidence of additive activity several tumor types. This phase III study evaluated efficacy durvalumab (an anti-PD-L1 monoclonal antibody) or plus tremelimumab anti-CTLA-4 versus standard care (SoC) R/M HNSCC...
IntroductionIn CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) less (prespecified descriptive analysis). We report results minimum 4 years' follow-up.MethodsAdults previously untreated stage IV recurrent NSCLC were randomized (1:1:1) ipilimumab, nivolumab, (PD-L1 ≥1%); chemotherapy, <1%). Efficacy included OS and other measures. Safety timing...